SODIUM OXYBATE - Generic Drug Details

What are the generic drug sources for sodium oxybate and what is the scope of freedom to operate?

Sodium oxybate is the generic ingredient in three branded drugs marketed by Avadel Cns, Amneal, Ascent Pharms Inc, Hikma, and Jazz Pharms, and is included in five NDAs. There are thirty-eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Sodium oxybate has sixty-eight patent family members in twenty-three countries.

There are five drug master file entries for sodium oxybate. Seven suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for SODIUM OXYBATE

International Patents:	68
US Patents:	38
Tradenames:	3
Applicants:	5
NDAs:	5
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	39
Clinical Trials:	56
Patent Applications:	2,147
Drug Prices:	Drug price trends for SODIUM OXYBATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SODIUM OXYBATE
What excipients (inactive ingredients) are in SODIUM OXYBATE?	SODIUM OXYBATE excipients list
DailyMed Link:	SODIUM OXYBATE at DailyMed

See drug prices for SODIUM OXYBATE

Recent Clinical Trials for SODIUM OXYBATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kristina Simonyan	PHASE1
Stanford University	PHASE4
Stanford University	PHASE2

See all SODIUM OXYBATE clinical trials

Generic filers with tentative approvals for SODIUM OXYBATE

Applicant	Application No.	Strength	Dosage Form
		500MG/ML	SOLUTION;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for SODIUM OXYBATE

Drug Class	Central Nervous System Depressant
Physiological Effect	Central Nervous System Depression Decreased Central Nervous System Organized Electrical Activity

Medical Subject Heading (MeSH) Categories for SODIUM OXYBATE

Adjuvants, Anesthesia

Anesthetics, Intravenous

Anatomical Therapeutic Chemical (ATC) Classes for SODIUM OXYBATE

N01AX	Other general anesthetics
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for SODIUM OXYBATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYREM	Oral Solution	sodium oxybate	500 mg/mL	021196	1	2010-07-08

US Patents and Regulatory Information for SODIUM OXYBATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-002	May 1, 2023		RX	Yes	No	12,097,176
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-001	May 1, 2023		RX	Yes	Yes	12,226,377		Y
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-004	May 1, 2023		RX	Yes	No	12,303,478
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-002	May 1, 2023		RX	Yes	No	11,839,597		Y
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-003	May 1, 2023		RX	Yes	No	12,144,793		Y
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-004	May 1, 2023		RX	Yes	No	11,400,065

EU/EMA Drug Approvals for SODIUM OXYBATE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma Ltd	Xyrem	sodium oxybate	EMEA/H/C/000593Treatment of narcolepsy with cataplexy in adult patients.	Authorised	no	no	no	2005-10-13
D&A Pharma	Hopveus	sodium oxybate	EMEA/H/C/004962Substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. Treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended.	Refused	no	no	no		2020-07-06

International Patents for SODIUM OXYBATE

Country	Patent Number	Title	Estimated Expiration
Australia	2023203055
Hong Kong	1256965	γ羥基丁酸與單羧酸轉運蛋白的施用 (ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS)
China	113473980	在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 (GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE)
European Patent Office	3487483	FORMULATIONS À LIBÉRATION MODIFIÉE DE GAMMA-HYDROXYBUTYRATE AYANT UNE PHARMACOCINÉTIQUE AMÉLIORÉE (MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS)
Australia	2025248712
China	119868330	在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 (Gamma-hydroxybutyrate compositions with improved pharmacokinetics in eating state)

Supplementary Protection Certificates for SODIUM OXYBATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	SPC/GB14/041	United Kingdom		PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTERED: UK EU/1/13/892/001-006 20140121
2203431	92666	Luxembourg		PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
2932970	SPC/GB18/041	United Kingdom		PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518
1948158	93075	Luxembourg		PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
2822954	1890030-8	Sweden		PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625

SODIUM OXYBATE Market Analysis and Financial Projection

Last updated: February 7, 2026

What Are the Market Dynamics for Sodium Oxybate?

Sodium oxybate, marketed as Xyrem by Jazz Pharmaceuticals, is primarily used to treat narcolepsy and cataplexy. Its unique mechanism as a central nervous system depressant, combined with regulatory controls, influences its market environment.

Market Drivers

• Growing Narcolepsy Diagnosis: The prevalence of narcolepsy increased globally, partially driven by better diagnostic techniques. The U.S. Census Bureau estimates narcolepsy affects around 1 in 2,000 people, translating to approximately 150,000 patients nationwide [1].
• Limited Competition: Few drugs serve as effective treatments for narcolepsy and cataplexy. Sodium oxybate remains the primary approved medication with evidence for efficacy.
• Regulatory Exclusivity: Jazz Pharmaceuticals holds patent protections and exclusive rights, delaying generic entry and maintaining pricing power.
• Reimbursement Policies: Insurance coverage is generally favorable due to the drug's approved indications, supporting consistent sales.

Market Constraints

• Strict Regulations: As a Schedule III controlled substance, sodium oxybate faces quotas and prescribing restrictions, limiting prescribing flexibility and volume growth.
• Safety Profile and Abuse Potential: Risks of misuse and abuse contribute to regulatory oversight, impacting market expansion.
• Pricing and Access: High costs, driven by limited competition, restrict access for some patients, especially where insurance coverage is inadequate.

Market Opportunities

• Expanding Indications: Research into additional uses, such as alcohol use disorder or fibromyalgia, presents potential growth pathways.
• New Formulations: Development of formulations with lower abuse risk or improved administration may broaden patient acceptance.
• Emerging Markets: Growing healthcare infrastructure and narcolepsy awareness expand potential patient populations in Asia and Latin America.

Market Size and Forecast

Jazz Pharmaceuticals reports that sodium oxybate generated approximately $930 million in revenue in 2022, with steady growth driven by increased diagnosis rates and expanded access programs [2].

The global narcolepsy drug market, including sodium oxybate and alternatives, is projected to grow at a CAGR of 5% between 2023 and 2030, reaching an estimated $2.2 billion by 2030 [3].

How Is the Financial Trajectory Shaping?

Revenue Trends

• Stable but Mature: Sodium oxybate remains Jazz Pharmaceuticals’ leading revenue source. Sales have shown resilience with modest growth, punctuated by market saturation and patent protections.
• Impact of Generic Entry: Patent expiration for Xyrem is anticipated in 2024, possibly leading to the entry of generic competitors, which could depress prices and margins [4].

Cost Structure

• Manufacturing Expenses: Production involves complex synthesis and strict quality controls, contributing to high manufacturing costs.
• Regulatory Compliance: Ongoing expenses related to compliance with DEA regulations and safety monitoring are significant.
• Marketing and Education: Heavy investment in physician education and patient awareness programs sustain prescriber adherence.

Profitability Outlook

• Margins: Current gross margins exceed 80% due to premium pricing and limited competition. However, impending patent loss may pressure margins.
• Post-Patent Scenario: Market analysts forecast a decline in revenue of up to 40% within two years of generic entry unless new indications or formulations mitigate losses.

Strategic Initiatives

• Pipeline Development: Jazz Pharma examines derivatives or alternative delivery systems to extend product life cycles.
• Partnerships and Licensing: Collaborations for new indications or acquisitions of smaller biotech firms diversify revenue streams.

What Are the Key Risks and Opportunities?

• Regulatory Changes: Stricter scheduling or restricted prescribing guidelines could limit market access.
• Legal Challenges: Patent litigation and generic price erosion pose threats.
• Market Expansion: Addressing unmet needs in other neurological or sleep disorders presents long-term growth potential.
• Reformulation Efforts: Developing abuse-deterrent formulations aims to reduce regulatory risks and expand prescribing.

Summary

Sodium oxybate's current market dominance is supported by high efficacy, regulatory exclusivity, and limited competition. However, patent expiration circa 2024 threatens to erode revenue streams unless strategic measures are successful. Growth projections remain favorable for now but depend on the company’s ability to innovate and expand indications.

Key Takeaways

• Sodium oxybate generated approximately $930 million in 2022 revenue.
• Patent expiration is expected in 2024, risking substantial revenue decline.
• The global narcolepsy drug market may reach $2.2 billion by 2030, growing at 5% annually.
• Regulatory restrictions and abuse potential impose market constraints.
• Expansion into new indications and formulations offers growth avenues.

FAQs

1. When will sodium oxybate face generic competition?
Patent protections expire in 2024 [4].

2. What are the primary indications for sodium oxybate?
Narcolepsy with cataplexy and excessive daytime sleepiness [2].

3. How does regulation influence sodium oxybate sales?
Strict scheduling and prescribing restrictions limit volume growth but also sustain high prices due to control measures.

4. What potential does the drug have beyond narcolepsy?
Research into applications for alcohol use disorder and other sleep-related conditions is ongoing.

5. How does Jazz Pharmaceuticals plan to sustain revenue post-patent?
By developing new formulations, exploring additional indications, and expanding into emerging markets.

---

References

[1] CDC. Narcolepsy Fact Sheet. Centers for Disease Control and Prevention, 2022.

[2] Jazz Pharmaceuticals. Xyrem Sales Data, 2022.

[3] MarketWatch. Global Narcolepsy Market Report, 2023.

[4] U.S. Patent and Trademark Office. Patent expiry notices for Xyrem, 2024.